VBI Vaccines Inc. (VBIV) stock plunged 4.81% in the pre-market trading session at the price of $2.97 after it presented data from Phase 2a study of VBI-1901 at the World Vaccine & Immunotherapy Congress. The company has also announced FDA approval of PreHevbrio. VBI Vaccines Inc. is an immunology-driven biopharmaceutical firm that works on the prevention and treatment of disease.
Data Presentation of VBI-1901 at World Vaccine & Immunotherapy Congress
On 1st December 2021, VBIV presented overall survival data from Phase 2a study of VBI-1901 at the World Vaccine & Immunotherapy Congress. The presentation was given by the Chief Scientific Officer of VBIV, David E. Anderson. VBI-1901 is the cancer vaccine immunotherapeutic candidate that targets recurrent glioblastoma.
VBIV Management Comments
Dr. Anderson remarked that they are very excited to publish this data at the World Vaccine & Immunotherapy Congress. They are happy for the patient who had attained a 93% tumor reduction. They believe VBI-1901 has the potential to become a significant addition to a treatment field with limited options. VBIV looks forward to assessing VBI-1901 in cany and chronic GBM conditions. Their product candidate is a hope for patients fighting devastating brain cancer, he added.
VBIV Reported FDA Approval of PreHevbrio
On 1st December 2021, VBIV published the approval of PreHevbrio by the Food and Drug Administration (FDA). PreHevbrio includes the S, pre-S2, and pre-S1 HBV surface antigens and inhibits infection caused by the hepatitis B virus (HBV). The vaccine is the only authorized 3-antigen HBV vaccine for adults in the United States.
Management Comments
President and CEO of VBIV, Jeff Baxter, stated that they are proud to publish the approval of PreHevbrio by FDA. This achievement confirms their ability to advance vaccine candidates from clinical development to final approval. This approval is the first move in their mission to help strengthen the public health efforts by defeating adult HBV viruses. He thanked the clinical site researchers, study participants, and employees for their participation in the study. The company looks onward to working with public health sectors in the battle against hepatitis B, he added.
